CA2480287C - Stable hydrate of a muscarinic receptor antagonist - Google Patents

Stable hydrate of a muscarinic receptor antagonist Download PDF

Info

Publication number
CA2480287C
CA2480287C CA2480287A CA2480287A CA2480287C CA 2480287 C CA2480287 C CA 2480287C CA 2480287 A CA2480287 A CA 2480287A CA 2480287 A CA2480287 A CA 2480287A CA 2480287 C CA2480287 C CA 2480287C
Authority
CA
Canada
Prior art keywords
bladder
hydrate
medical condition
urinary
neurogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2480287A
Other languages
English (en)
French (fr)
Other versions
CA2480287A1 (en
Inventor
Peter James Dunn
John George Matthews
Trevor Jack Newbury
Garry O'connor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Searchlight Pharma Inc
Original Assignee
Novartis International Pharmaceutical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9933731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2480287(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis International Pharmaceutical Ltd filed Critical Novartis International Pharmaceutical Ltd
Publication of CA2480287A1 publication Critical patent/CA2480287A1/en
Application granted granted Critical
Publication of CA2480287C publication Critical patent/CA2480287C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2480287A 2002-03-26 2003-03-17 Stable hydrate of a muscarinic receptor antagonist Expired - Lifetime CA2480287C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0207104.1 2002-03-26
GBGB0207104.1A GB0207104D0 (en) 2002-03-26 2002-03-26 Stable hydrate of a muscarinic receptor antagonist
PCT/IB2003/001043 WO2003080599A1 (en) 2002-03-26 2003-03-17 Stable hydrate of a muscarinic receptor antagonist

Publications (2)

Publication Number Publication Date
CA2480287A1 CA2480287A1 (en) 2003-10-02
CA2480287C true CA2480287C (en) 2011-05-31

Family

ID=9933731

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2480287A Expired - Lifetime CA2480287C (en) 2002-03-26 2003-03-17 Stable hydrate of a muscarinic receptor antagonist

Country Status (22)

Country Link
US (3) US6930188B2 (enExample)
EP (2) EP2336124B1 (enExample)
JP (2) JP2005524678A (enExample)
KR (4) KR101026283B1 (enExample)
CN (1) CN100345840C (enExample)
AR (1) AR042608A1 (enExample)
AT (1) ATE495169T1 (enExample)
AU (1) AU2003209921A1 (enExample)
BR (2) BRPI0308706B8 (enExample)
CA (1) CA2480287C (enExample)
CY (2) CY1111200T1 (enExample)
DE (1) DE60335711D1 (enExample)
DK (2) DK2336124T3 (enExample)
ES (2) ES2358644T3 (enExample)
GB (1) GB0207104D0 (enExample)
PA (1) PA8569701A1 (enExample)
PT (2) PT1490357E (enExample)
SI (2) SI2336124T1 (enExample)
SV (1) SV2003001515A (enExample)
TW (1) TW200306816A (enExample)
UY (1) UY27735A1 (enExample)
WO (1) WO2003080599A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
JP2008538784A (ja) * 2005-04-24 2008-11-06 ワイス 膀胱機能を調節するための方法
WO2007076159A2 (en) * 2005-12-27 2007-07-05 Teva Pharmaceutical Industries Ltd. Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof
EP2109601A2 (en) * 2007-01-05 2009-10-21 Dr. Reddy's Laboratories Ltd. Preparation of darifenacin and its salts
KR101495708B1 (ko) * 2007-02-23 2015-02-25 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 무스카린 수용체 안타고니스트로 유용한 4차 암모늄 디페닐메틸 화합물
WO2008144602A1 (en) * 2007-05-18 2008-11-27 Auspex Pharmaceuticals, Inc. Deuterated zamifenacin derivatives
US20100204296A1 (en) * 2007-06-08 2010-08-12 Actavis Group Ptc Ehf Novel Polymorphs of Darifenacin Free Base and its Hydrobromide Salt
WO2009006413A1 (en) * 2007-06-30 2009-01-08 Auspex Pharmaceuticals, Inc. Substituted pyrrolidines
US20090018346A1 (en) * 2007-07-13 2009-01-15 Medichem, S.A. Amorphous Form Of Darifenacin Hydrobromide And Processes For The Preparation Thereof
CZ300895B6 (cs) * 2008-01-28 2009-09-02 Zentiva, A. S. Zpusob prípravy Darifenacinu
WO2009125426A2 (en) * 2008-02-08 2009-10-15 Neuland Laboratories Ltd NOVEL PROCESS FOR THE PREPARATION OF (3SM-[2-(2 J-DIHYDRO-5- BENZOFURANYLϊETHYL]-α.α -DIPHENYL-3-PYRROLIDINEACETAMIDE HYDROBROMIDE
JP5450387B2 (ja) 2008-04-02 2014-03-26 株式会社カネカ （ｓ）−３−（１−シアノ−１，１−ジフェニルメチル）−ピロリジンの製造法
US20110144354A1 (en) * 2008-09-22 2011-06-16 Watson Pharma Private Limited Process for Preparation of Darifenacin and Intermediates Used in the Process
EP2236509A1 (en) 2009-04-01 2010-10-06 Ragactives, S.L. Method for obtaining 1,3-difunctionalized pyrrolidine derivatives
WO2011070419A1 (en) 2009-12-10 2011-06-16 Aurobindo Pharma Limited An improved process for the preparation of darifenacin hydrobromide
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2017106175A2 (en) * 2015-12-14 2017-06-22 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DYSFUNCTION
WO2018029140A1 (de) * 2016-08-12 2018-02-15 Bayer Cropscience Aktiengesellschaft Verfahren zur herstellung von substituierten styrol-derivaten
WO2019053051A1 (en) * 2017-09-12 2019-03-21 Lts Lohmann Therapie-Systeme Ag MICRO NEEDLE IONTOPHORESIS DEVICE

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5233053A (en) * 1989-03-17 1993-08-03 Pfizer Inc. Pyrrolidine derivatives
GB8906166D0 (en) * 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9400600D0 (en) * 1994-01-14 1994-03-09 Pfizer Ltd Treatment of motion seckness
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9612710D0 (en) * 1996-06-18 1996-08-21 Pfizer Ltd Method of treatment
KR20010029519A (ko) * 1996-09-19 2001-04-06 이곤 이 버그 요실금 치료 방법
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist

Also Published As

Publication number Publication date
US20030191176A1 (en) 2003-10-09
PT2336124E (pt) 2012-12-12
GB0207104D0 (en) 2002-05-08
ES2358644T3 (es) 2011-05-12
SV2003001515A (es) 2003-12-15
ATE495169T1 (de) 2011-01-15
EP2336124B1 (en) 2012-08-29
HK1156626A1 (en) 2012-06-15
KR20110130539A (ko) 2011-12-05
BRPI0308706B8 (pt) 2021-05-25
HK1080847A1 (zh) 2006-05-04
US20080167367A1 (en) 2008-07-10
PA8569701A1 (es) 2003-12-10
JP2005524678A (ja) 2005-08-18
CA2480287A1 (en) 2003-10-02
SI1490357T1 (sl) 2011-05-31
CY1113433T1 (el) 2016-06-22
KR20100101182A (ko) 2010-09-16
AR042608A1 (es) 2005-06-29
US7696357B2 (en) 2010-04-13
US20050245597A1 (en) 2005-11-03
DK1490357T3 (da) 2011-04-04
AU2003209921A1 (en) 2003-10-08
KR20120098888A (ko) 2012-09-05
CY1111200T1 (el) 2015-06-11
EP1490357B1 (en) 2011-01-12
BR122018000397B1 (pt) 2019-07-02
SI2336124T1 (sl) 2012-12-31
BR122018000397B8 (pt) 2021-07-27
KR101212908B1 (ko) 2012-12-14
WO2003080599A1 (en) 2003-10-02
CN100345840C (zh) 2007-10-31
JP2010195828A (ja) 2010-09-09
PT1490357E (pt) 2011-03-01
EP2336124A1 (en) 2011-06-22
CN1642945A (zh) 2005-07-20
UY27735A1 (es) 2003-10-31
BR0308706A (pt) 2005-01-04
BRPI0308706B1 (pt) 2018-07-10
EP1490357A1 (en) 2004-12-29
ES2394067T3 (es) 2013-01-16
KR101026283B1 (ko) 2011-03-31
DK2336124T3 (da) 2012-12-17
US6930188B2 (en) 2005-08-16
KR20040093477A (ko) 2004-11-05
DE60335711D1 (de) 2011-02-24
TW200306816A (en) 2003-12-01

Similar Documents

Publication Publication Date Title
US7696357B2 (en) Stable hydrate of a muscarinic receptor antagonist
US7423040B2 (en) Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same
KR20020032627A (ko) 다형태 염
JP3857919B2 (ja) ４−アミノ−６，７−ジメトキシ−２−（５−メタンスルホンアミド−１，２，３，４−テトラヒドロイソキノル−２−イル）−５−（２−ピリジル）キナゾリンメシラートおよび多形
HK1156626B (en) Stable hydrate of a muscarinic receptor antagonist
HUP0100343A2 (hu) A 2-{2-[4[bisz-(4-fluor-fenil)-metil]-1-piperazinil]-etoxi}-ecetsav-dihidroklorid új pszeudopolimorf kristályos formái, azok előállítására alkalmas eljárások és ilyen kristályos formákat tartalmazó gyógyszerkészítmények
CN117447385A (zh) 氘代的3-氨甲基-4-苯基哌啶-4-醇类化合物的制备及其用途
HK1080847B (en) Stable hydrate of a muscarinic receptor antagonist
ES2262515T3 (es) R-hidroxinefazodona.
MXPA00000507A (en) Thermodynamically stable modification of 1-(4-carbazolyloxy)-3- [2-(2-methoxyphenoxy)ethylamino]-2- propanole, process for its preparation and pharmaceutical compositions containing it

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20230317